micro-community-banner
 
  • Saved

2yr
BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia

BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia

Source : https://www.sciencedirect.com/science/article/abs/pii/S0889858823000394?via=ihub

Data regarding ibrutinib therapy in the first line or TN patients with WM emanate primarily from 3 prospective studies, each of which differ in design but from which one can...

Summary: BTK inhibitors have demonstrated clinically meaningful efficacy in patients with previously untreated WM. In a head-to-head comparison with ibrutinib, zanubrutinib was not significantly superior to ibrutinib but provided faster and deeper response in CXCR4-mutated patients. Furthermore, unlike ibrutinib, second-generation BTK...

  • Saved

2yr
A Preview into the European Hematology Association (EHA) Hybrid Congress

Highlights of the Congress include:

  • More than 1,300 posters featuring the latest research in the field of hematology
  • Joint symposia with other professional and patient organizations
  • Interactive workshops and special sessions focusing on topics in novel formats, including YoungEHA sessions
  • Thematic debates grappling with critical questions for research and practice
  • Saved

2yr
MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma - PubMed

MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37226519/

Lymphocyte proliferation and tumourigenesis are dependent on nucleotide synthesis to support DNA, RNA and phospholipid synthesis. Here, we identified that reprogramming of nucleotide metabolism as an important factor divides mantle...

Relevance: Lymphocyte proliferation and tumourigenesis are dependent on nucleotide synthesis to support DNA, RNA and phospholipid synthesis. Here, we identified that reprogramming of nucleotide metabolism as an important factor divides mantle cell lymphoma (MCL) into two groups with different transcriptional signalling pathways and varying...

  • Saved

2yr
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE - PubMed

Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37204683/

Regimens based on Bruton's tyrosine kinase inhibitors (BTKi) have been increasingly used to treat mantle cell lymphoma (MCL). A real-world multicenter study was conducted to characterize treatment patterns and outcomes...

Relevance: Regimens based on Bruton's tyrosine kinase inhibitors (BTKi) have been increasingly used to treat mantle cell lymphoma (MCL). A real-world multicenter study was conducted to characterize treatment patterns and outcomes in patients with newly diagnosed MCL by Chinese Hematologist and Oncologist Innovation Cooperation of the...

  • Saved

2yr
Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study - PubMed

Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37199050/

R-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma.

Conclusion: R-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma.